AU1728995A - Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides - Google Patents

Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides

Info

Publication number
AU1728995A
AU1728995A AU17289/95A AU1728995A AU1728995A AU 1728995 A AU1728995 A AU 1728995A AU 17289/95 A AU17289/95 A AU 17289/95A AU 1728995 A AU1728995 A AU 1728995A AU 1728995 A AU1728995 A AU 1728995A
Authority
AU
Australia
Prior art keywords
vacuolar
atpase
inhibition
phosphorothioate oligonucleotides
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17289/95A
Inventor
Cy A. Stein
John L Tonkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of AU1728995A publication Critical patent/AU1728995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/313Phosphorodithioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3511Conjugate intercalating or cleaving agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU17289/95A 1994-01-19 1995-01-18 Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides Abandoned AU1728995A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US184244 1988-04-21
US18424494A 1994-01-19 1994-01-19
PCT/US1995/000726 WO1995020043A1 (en) 1994-01-19 1995-01-18 Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides

Publications (1)

Publication Number Publication Date
AU1728995A true AU1728995A (en) 1995-08-08

Family

ID=22676135

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17289/95A Abandoned AU1728995A (en) 1994-01-19 1995-01-18 Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides

Country Status (2)

Country Link
AU (1) AU1728995A (en)
WO (1) WO1995020043A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ051099A0 (en) 1999-05-24 1999-06-17 Tachas, George Dr Novel products and processes in treatment and/or prophylaxis
CN1331216A (en) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 Polypeptide-human vacuolus hydrion ATP enzyme 36.08 and polynucleotide for coding it
GB0102562D0 (en) * 2001-02-01 2001-03-21 Unilever Plc Cosmetic products for the reduction of sweat acidity
EP1642585A1 (en) * 2004-09-27 2006-04-05 Immunotech S.A. Osteogenic oligonucleotides and uses thereof
CA2624686A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses

Also Published As

Publication number Publication date
WO1995020043A1 (en) 1995-07-27

Similar Documents

Publication Publication Date Title
AU2657095A (en) Synthesis of oligonucleotides
AU3775593A (en) Process for preparing phosphorothioate oligonucleotides
AU3222795A (en) Antitumor antisense oligonucleotides
AU4172599A (en) A process for inhibiting expression of genes
AU5441896A (en) Cooperative oligonucleotides
EP1143953A3 (en) Method of inhibiting angiogenesis
GB9514437D0 (en) Inhibition of gene expression
AU1771195A (en) Method of administering azithromycin
AU3180795A (en) Hydrate inhibition
AU3634095A (en) Inhibition of hemoflagellates by camptothecin compounds
AU4778196A (en) Hydrosilylation of unsaturated compounds
AU5737696A (en) Nucleic acids for treating obesity
GB9514435D0 (en) Inhibition of gene expression
ZA969186B (en) Inhibition of amyloidosis by 9-acridinones
AU3512595A (en) Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
AU6601690A (en) Selective inhibition of gene expression by photoactivatable oligonucleotides
AU6615500A (en) Preventing immune-mediated abortion by inhibiting costimulation
EP0846697A4 (en) Process for the preparation of erythromycin derivatives
AU2585197A (en) Antisense approach to gene inhibition
AU1728995A (en) Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides
AU3126495A (en) Process for making alkyl polyglycosides
AU3717895A (en) Inhibition of plasmodia parasites by camptothecin compounds
AU3731595A (en) Improved process for the preparation of 5-aminotetrazole
HUP9601261A2 (en) Process for preparation of 2-fluor-pirimidine-derivatives
AU7674796A (en) Method for treating anxiety